Cargando…
Essential tuberculosis medicines and health outcomes in countries with a national essential medicines list
BACKGROUND: Tuberculosis (TB) remains a major cause of morbidity and mortality globally despite effective treatments. Along with high-quality health services, essential medicines are a key tool in curbing TB related mortality. Examining relationships between listing TB medicines on national essentia...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924688/ https://www.ncbi.nlm.nih.gov/pubmed/35308809 http://dx.doi.org/10.1016/j.jctube.2022.100305 |
_version_ | 1784669914208927744 |
---|---|
author | Maraj, Darshanand Steiner, Liane Persaud, Nav |
author_facet | Maraj, Darshanand Steiner, Liane Persaud, Nav |
author_sort | Maraj, Darshanand |
collection | PubMed |
description | BACKGROUND: Tuberculosis (TB) remains a major cause of morbidity and mortality globally despite effective treatments. Along with high-quality health services, essential medicines are a key tool in curbing TB related mortality. Examining relationships between listing TB medicines on national essential medicines lists (NEMLs) and population health outcomes related to amenable mortality is one way to assess TB care. METHODS: In this cross-sectional study of 137 countries, we used linear regression to examine the relationship between the number of TB medicines listed on NEMLs and TB related mortality while controlling for country income, region and TB burden. RESULTS: Most countries listed essential TB medicines to treat latent, drug-sensitive and disseminated TB but few listed enough for multi-drug resistant TB (MDR-TB) therapy. The total number of TB medicines listed ranged from 1 to 29 (median: 19, interquartile range: 15 to 22). Over 75% of the variation in health outcomes were explained by the number of TB medicines listed, gross domestic product (GDP) per capita, region and high-burden MDR-TB status. The number of TB medicines listed was not associated with TB mortality. CONCLUSION: Most countries list essential TB treatments and the variation in TB outcomes is explained by other factors such as GDP. |
format | Online Article Text |
id | pubmed-8924688 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-89246882022-03-17 Essential tuberculosis medicines and health outcomes in countries with a national essential medicines list Maraj, Darshanand Steiner, Liane Persaud, Nav J Clin Tuberc Other Mycobact Dis Article BACKGROUND: Tuberculosis (TB) remains a major cause of morbidity and mortality globally despite effective treatments. Along with high-quality health services, essential medicines are a key tool in curbing TB related mortality. Examining relationships between listing TB medicines on national essential medicines lists (NEMLs) and population health outcomes related to amenable mortality is one way to assess TB care. METHODS: In this cross-sectional study of 137 countries, we used linear regression to examine the relationship between the number of TB medicines listed on NEMLs and TB related mortality while controlling for country income, region and TB burden. RESULTS: Most countries listed essential TB medicines to treat latent, drug-sensitive and disseminated TB but few listed enough for multi-drug resistant TB (MDR-TB) therapy. The total number of TB medicines listed ranged from 1 to 29 (median: 19, interquartile range: 15 to 22). Over 75% of the variation in health outcomes were explained by the number of TB medicines listed, gross domestic product (GDP) per capita, region and high-burden MDR-TB status. The number of TB medicines listed was not associated with TB mortality. CONCLUSION: Most countries list essential TB treatments and the variation in TB outcomes is explained by other factors such as GDP. Elsevier 2022-02-23 /pmc/articles/PMC8924688/ /pubmed/35308809 http://dx.doi.org/10.1016/j.jctube.2022.100305 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Maraj, Darshanand Steiner, Liane Persaud, Nav Essential tuberculosis medicines and health outcomes in countries with a national essential medicines list |
title | Essential tuberculosis medicines and health outcomes in countries with a national essential medicines list |
title_full | Essential tuberculosis medicines and health outcomes in countries with a national essential medicines list |
title_fullStr | Essential tuberculosis medicines and health outcomes in countries with a national essential medicines list |
title_full_unstemmed | Essential tuberculosis medicines and health outcomes in countries with a national essential medicines list |
title_short | Essential tuberculosis medicines and health outcomes in countries with a national essential medicines list |
title_sort | essential tuberculosis medicines and health outcomes in countries with a national essential medicines list |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924688/ https://www.ncbi.nlm.nih.gov/pubmed/35308809 http://dx.doi.org/10.1016/j.jctube.2022.100305 |
work_keys_str_mv | AT marajdarshanand essentialtuberculosismedicinesandhealthoutcomesincountrieswithanationalessentialmedicineslist AT steinerliane essentialtuberculosismedicinesandhealthoutcomesincountrieswithanationalessentialmedicineslist AT persaudnav essentialtuberculosismedicinesandhealthoutcomesincountrieswithanationalessentialmedicineslist |